Bionano Genomics (BNGO) 10-Q 3 Nov 22 2022 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Sep. 30, 2022	Oct. 26, 2022
Document Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2022
Document Transition Report	false
Entity File Number	001-38613
Entity Registrant Name	Bionano Genomics, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	26-1756290
Entity Address, Address Line One	9540 Towne Centre Drive, Suite 100
Entity Address, City or Town	San Diego
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	92121
City Area Code	858
Local Phone Number	888-7600
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding (in shares)		296,924,500
Amendment Flag	false
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q3
Entity Central Index Key	0001411690
Current Fiscal Year End Date	--12-31
Common Stock
Document Information [Line Items]
Title of 12(b) Security	Common Stock, $0.0001 par value per share
Trading Symbol	BNGO
Security Exchange Name	NASDAQ
Warrants to purchase Common Stock
Document Information [Line Items]
Title of 12(b) Security	Warrants to purchase Common Stock
Trading Symbol	BNGOW
Security Exchange Name	NASDAQ

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 28,166	$ 24,571
Investments	152,024	226,041
Accounts receivable, net of allowance for doubtful accounts of $496,000 and $690,000 as of September 30, 2022 and December 31, 2021, respectively	5,829	4,934
Inventory	25,046	12,387
Prepaid expenses and other current assets	7,132	4,481
Total current assets	218,197	272,414
Property and equipment, net	15,859	10,318
Operating lease right-of-use assets	6,030	6,691
Finance lease right-of-use assets, related party	3,759	3,926
Intangible assets, net	22,585	26,842
Goodwill	56,466	56,160
Other long-term assets	802	749
Total assets	323,698	377,100
Current liabilities:
Accounts payable	9,407	9,696
Accrued expenses	11,742	9,694
Contract liabilities	976	684
Operating lease liability	1,784	1,467
Finance lease liability, related party	288	299
Contingent consideration	9,303	0
Total current liabilities	33,500	21,840
Operating lease liability, net of current portion	4,694	5,288
Finance lease liability, net of current portion, related party	3,626	3,642
Contingent consideration	0	9,066
Long-term contract liabilities	136	146
Total liabilities	41,956	39,982
Commitments and contingencies (Note 7)
Stockholders’ equity:
Preferred stock, $0.0001 par value; 10,000,000 shares authorized and no shares issued or outstanding as of September 30, 2022 and December 31, 2021	0	0
Common stock, $0.0001 par value, 400,000,000 shares authorized at September 30, 2022 and December 31, 2021; 296,900,000 and 289,602,000 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively	30	29
Additional paid-in capital	593,572	553,747
Accumulated deficit	(310,038)	(216,119)
Accumulated other comprehensive loss	(1,822)	(539)
Total stockholders’ equity	281,742	337,118
Total liabilities and stockholders’ equity	$ 323,698	$ 377,100

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Allowance for doubtful accounts	$ 496	$ 690
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	10,000,000	10,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	400,000,000	400,000,000
Common stock, shares issued (in shares)	296,900,000	289,602,000
Common stock, shares outstanding (in shares)	296,900,000	289,602,000

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Revenue:
Total revenue	$ 7,221	$ 4,655	$ 19,587	$ 11,679
Cost of revenue:
Total cost of revenue	5,412	3,501	15,447	8,044
Operating expenses:
Research and development	12,742	6,505	35,036	13,270
Selling, general and administrative	21,216	15,327	63,275	38,683
Total operating expenses	33,958	21,832	98,311	51,953
Loss from operations	(32,149)	(20,678)	(94,171)	(48,318)
Other income (expense):
Interest income	436	29	737	152
Interest expense	(73)	(2)	(223)	(873)
Gain on forgiveness of Paycheck Protection Program loan	0	0	0	1,775
Loss on debt extinguishment	0	0	0	(2,076)
Other income (expense)	5	(67)	(183)	(96)
Total other income (expense)	368	(40)	331	(1,118)
Loss before income taxes	(31,781)	(20,718)	(93,840)	(49,436)
Benefit (provision) for income taxes	(28)	(35)	(79)	(50)
Net loss	$ (31,809)	$ (20,753)	$ (93,919)	$ (49,486)
Net loss per share, basic (in dollars per share)	$ (0.11)	$ (0.07)	$ (0.33)	$ (0.18)
Net loss per share, diluted (in dollars per share)	$ (0.11)	$ (0.07)	$ (0.33)	$ (0.18)
Weighted-average common shares outstanding, basic (in shares)	289,701	280,173	286,629	274,392
Weighted-average common shares outstanding, diluted (in shares)	289,701	280,173	286,629	274,392
Product revenue
Revenue:
Total revenue	$ 3,606	$ 3,300	$ 10,635	$ 7,845
Cost of revenue:
Total cost of revenue	3,708	2,340	11,257	5,723
Service and other revenue
Revenue:
Total revenue	3,615	1,355	8,952	3,834
Cost of revenue:
Total cost of revenue	$ 1,704	$ 1,161	$ 4,190	$ 2,321

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Statement of Comprehensive Income [Abstract]
Net loss:	$ (31,809)	$ (20,753)	$ (93,919)	$ (49,486)
Other comprehensive loss:
Unrealized gain (loss) on investment securities	236	(116)	(1,143)	(116)
Foreign currency translation adjustments	(140)	0	(140)	0
Other comprehensive loss	96	(116)	(1,283)	(116)
Total comprehensive loss	$ (31,713)	$ (20,869)	$ (95,202)	$ (49,602)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Stockholders’ Equity (Deficit) (Unaudited) - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Accumulated Other Comprehensive Loss
Beginning Balance (in shares) at Dec. 31, 2020		189,953
Beginning Balance at Dec. 31, 2020	$ 35,082	$ 19	$ 178,747	$ (143,684)	$ 0
Equity
Stock option exercises (in shares)		102
Stock option exercises	333		333
Stock-based compensation expense	371		371
Issue common stock, net of issuance costs (in shares)		78,000
Issue common stock, net of issuance costs	327,486	$ 8	327,478
Issue stock for warrant exercises (in shares)		10,739
Issue stock for warrant exercises	9,393	$ 1	9,392
Net loss	(9,947)			(9,947)
Ending Balance (in shares) at Mar. 31, 2021		278,794
Ending Balance at Mar. 31, 2021	362,718	$ 28	516,321	(153,631)	0
Beginning Balance (in shares) at Dec. 31, 2020		189,953
Beginning Balance at Dec. 31, 2020	35,082	$ 19	178,747	(143,684)	0
Equity
Net loss	(49,486)
Other comprehensive income (loss)	(116)
Ending Balance (in shares) at Sep. 30, 2021		281,441
Ending Balance at Sep. 30, 2021	341,565	$ 28	534,823	(193,170)	(116)
Beginning Balance (in shares) at Mar. 31, 2021		278,794
Beginning Balance at Mar. 31, 2021	362,718	$ 28	516,321	(153,631)	0
Equity
Stock option exercises (in shares)		60
Stock option exercises	89		89
Stock-based compensation expense	1,758		1,758
Issue stock for employee stock purchase plan (in shares)		150
Issue stock for employee stock purchase plan	65		65
Issue stock for warrant exercises (in shares)		50
Issue stock for warrant exercises	22		22
Net loss	(18,786)			(18,786)
Ending Balance (in shares) at Jun. 30, 2021		279,054
Ending Balance at Jun. 30, 2021	345,866	$ 28	518,255	(172,417)	0
Equity
Stock option exercises (in shares)		209
Stock option exercises	242		242
Stock-based compensation expense	2,788		2,788
Issue common stock, net of issuance costs (in shares)		2,178
Issue common stock, net of issuance costs	13,537		13,537
Issue stock for warrant exercises	1		1
Net loss	(20,753)			(20,753)
Other comprehensive income (loss)	(116)				(116)
Ending Balance (in shares) at Sep. 30, 2021		281,441
Ending Balance at Sep. 30, 2021	341,565	$ 28	534,823	(193,170)	(116)
Beginning Balance (in shares) at Dec. 31, 2021		289,602
Beginning Balance at Dec. 31, 2021	337,118	$ 29	553,747	(216,119)	(539)
Equity
Stock option exercises (in shares)		21
Stock option exercises	15		15
Stock-based compensation expense	5,102		5,102
Issuance of common stock due to the vesting of restricted stock units, net of shares withheld to cover taxes (in shares)		65
Net loss	(29,952)			(29,952)
Other comprehensive income (loss)	(1,098)				(1,098)
Ending Balance (in shares) at Mar. 31, 2022		289,688
Ending Balance at Mar. 31, 2022	311,185	$ 29	558,864	(246,071)	(1,637)
Beginning Balance (in shares) at Dec. 31, 2021		289,602
Beginning Balance at Dec. 31, 2021	$ 337,118	$ 29	553,747	(216,119)	(539)
Equity
Stock option exercises (in shares)	402
Net loss	$ (93,919)
Other comprehensive income (loss)	(1,283)
Ending Balance (in shares) at Sep. 30, 2022		296,900
Ending Balance at Sep. 30, 2022	281,742	$ 30	593,572	(310,038)	(1,822)
Beginning Balance (in shares) at Mar. 31, 2022		289,688
Beginning Balance at Mar. 31, 2022	311,185	$ 29	558,864	(246,071)	(1,637)
Equity
Stock option exercises (in shares)		249
Stock option exercises	136		136
Stock-based compensation expense	5,777		5,777
Issuance of common stock due to the vesting of restricted stock units, net of shares withheld to cover taxes (in shares)		(26)
Issue stock for employee stock purchase plan (in shares)		150
Issue stock for employee stock purchase plan	75		75
Net loss	(32,158)			(32,158)
Other comprehensive income (loss)	(281)				(281)
Ending Balance (in shares) at Jun. 30, 2022		290,061
Ending Balance at Jun. 30, 2022	284,734	$ 29	564,852	(278,229)	(1,918)
Equity
Stock option exercises (in shares)		132
Stock option exercises	111		111
Stock-based compensation expense	6,059		6,059
Issuance of common stock due to the vesting of restricted stock units, net of shares withheld to cover taxes (in shares)		67
Issue common stock, net of issuance costs (in shares)		6,640
Issue common stock, net of issuance costs	22,551	$ 1	22,550
Net loss	(31,809)			(31,809)
Other comprehensive income (loss)	96				96
Ending Balance (in shares) at Sep. 30, 2022		296,900
Ending Balance at Sep. 30, 2022	$ 281,742	$ 30	$ 593,572	$ (310,038)	$ (1,822)

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Operating activities:
Net loss	$ (93,919)	$ (49,486)
Adjustments to reconcile net loss to net cash used by operating activities:
Depreciation and amortization expense	6,855	1,490
Amortization of financing lease right-of-use asset	168	0
Amortization of interest on securities	695	0
Non-cash lease expense	383	0
Non-cash interest expense	0	178
Stock-based compensation	16,938	4,917
Provision for bad debt expense	33	0
Change in fair value of contingent consideration	237	0
Gain on forgiveness of PPP Loan	0	(1,775)
Loss on debt extinguishment	0	2,076
Cost of leased equipment sold to customer	204	0
Changes in operating assets and liabilities:
Accounts receivable	(1,167)	(336)
Inventory	(18,121)	(10,346)
Prepaid expenses and other current assets	(3,439)	(2,072)
Accounts payable	(1,233)	4,945
Accrued expenses and contract liabilities	2,067	4,104
Net cash used in operating activities	(90,299)	(46,305)
Investing Activities:
BioDiscovery acquisition, return of purchase consideration from escrow	694	0
Purchases of property and equipment	(1,055)	(344)
Purchase of available for sale securities	(63,208)	(205,334)
Sale and maturity of available for sale securities	135,386	20,000
Construction in progress	(686)	0
Sale of property and equipment	26	126
Net cash provided by / (used in) investing activities	71,157	(185,552)
Financing activities:
Repayment of term-loan debt	0	(17,010)
Principal payments of financing lease liability	(26)	0
Proceeds from sale of common stock	23,128	342,712
Offering expenses on sale of common stock	(578)	(1,704)
Proceeds from sale of common stock under employee stock purchase plan	75	65
Proceeds from warrant and option exercises	262	10,081
Net cash provided by financing activities	22,861	334,144
Effect of exchange rates on cash and cash equivalents	(124)	0
Net increase in cash and cash equivalents	3,595	102,287
Cash and cash equivalents at beginning of period	24,571	38,449
Cash and cash equivalents at end of period	28,166	140,736
Supplemental cash flow disclosures:
Cash paid for interest	222	490
Cash paid for operating lease liabilities	1,166	660
Supplemental disclosure of non-cash investing and financing activities:
Transfer of instruments and servers from inventory to property and equipment, net	5,500	4,530
Property and equipment costs incurred but not paid included in accounts payable and accrued expenses	857	0
Construction in progress included in accounts payable	106	0
Operating lease liabilities resulting from obtaining right-of-use assets	517	2,309
Forgiveness of PPP Loan	0	1,775
Stock issued for services	0	15
Warrant exercise pursuant to cashless exercise	$ 0	$ 129

Organization and Basis of Prese

Organization and Basis of Presentation	9 Months Ended
	Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Basis of Presentation	Organization and Basis of Presentation Description of Business Bionano Genomics, Inc. (collectively, with its consolidated subsidiaries, the “Company”) is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company’s mission is to transform the way the world sees the genome through optical genome mapping (“OGM”) solutions, diagnostic services and software. The Company offers OGM solutions for applications across basic, translational and clinical research, and for other applications including bioprocessing. Through its Lineagen, Inc. (doing business as Bionano Laboratories, “Bionano Laboratories”) business, the Company also provides diagnostic testing for patients with clinical presentations consistent with autism spectrum disorder and other neurodevelopmental disabilities. Through its BioDiscovery, LLC (“BioDiscovery”) business, the Company also offers an industry-leading, platform-agnostic software solution, which integrates next-generation sequencing and microarray data designed to provide analysis, visualization, interpretation and reporting of copy number variants, single-nucleotide variants and absence of heterozygosity across the genome in one consolidated view. Basis of Presentation The accompanying financial information has been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) for interim reporting purposes. The condensed consolidated financial statements are unaudited. The unaudited condensed consolidated financial statements reflect, in the opinion of the Company’s management, all adjustments, consisting of only normal recurring adjustments, necessary for a fair presentation of financial position, results of operations, changes in equity, and comprehensive loss and cash flows for each period presented in accordance with United States generally accepted accounting principles (“U.S. GAAP”). All intercompany transactions and balances have been eliminated. These interim unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021. Reclassifications Certain amounts reported in prior years have been reclassified to conform with the presentation in the current year. These reclassifications had no effect on the reported results of operations. Liquidity As of September 30, 2022, the Company had approximately $28.2 million in cash and cash equivalents, $152.0 million in available for sale investment securities, and working capital of $184.7 million as a result of common stock offerings executed in the quarters ended December 31, 2020, March 31, 2021, September 30, 2021, and September 30, 2022. The Company believes its available cash, cash equivalents, and available for sale securities will be sufficient to fund operations, obligations as they become due and capital investments for at least the next 12 months. However, the Company expects to continue to incur net losses for the foreseeable future. The Company plans to continue to fund its losses from operations and capital funding needs through a combination of equity offerings, debt financings or other sources, including potential collaborations, licenses and other similar arrangements. If the Company is not able to secure adequate additional funding, the Company may be forced to make reductions in spending, potentially harming the Company’s business. COVID-19 and Other Geopolitical Events The Company is subject to additional risks and uncertainties as a result of adverse geopolitical and macroeconomic events, such as the continued impact of COVID-19, the ongoing conflict between Ukraine and Russia and related sanctions, and uncertain market conditions, including higher inflation and supply chain disruptions, which could continue to have a material impact on the Company’s business and financial results. The Company closely monitors and complies with various applicable guidelines and legal requirements in the jurisdictions in which it operates, which may continue to result in reduced business operations in response to new or existing stay-at-home orders, travel restrictions and other social distancing measures. If restrictions related to COVID-19 persist, the Company could see additional supply chain disruptions that impact its ability to produce its products and may cause the Company to make strategic determinations regarding, among other things, the cost and quality of the components and supplies it acquires. The Company may also see negative effects on study enrollment in its ongoing or future studies. At various times throughout the pandemic, the Company has been unable to visit certain customer sites to support installation or service of its OGM systems. The Company’s manufacturing partners, suppliers, and customers, have implemented similar operational reductions. Despite reporting an increase in revenue for the three and nine months ended September 30, 2022 when compared to the same period in 2021, the Company experienced supply chain constraints that negatively impacted the Company’s first, second and third quarter 2021 and 2022 financial results. Given the continued evolution of the COVID-19 pandemic and the related complexities and uncertainties associated with the additional variants, the future effects of COVID-19 are unknown and the Company’s financial results may continue to be negatively affected in the future. The COVID-19 pandemic may also have long-term effects on the nature of the office environment and remote working, which may present strategy, operational, talent recruiting and retention and workplace culture challenges that may adversely affect its business. Following the recent invasion of Ukraine by Russia, the U.S. and global financial markets experienced volatility, which has led to disruptions to trade, commerce, pricing stability, credit availability, supply chain continuity and reduced access to liquidity globally. In response to the invasion, the United States, United Kingdom and European Union, along with others, imposed significant new sanctions and export controls against Russia, Russian banks and certain Russian individuals and may implement additional sanctions or take further punitive actions in the future. The full economic and social impact of the sanctions imposed on Russia and possible future punitive measures that may be implemented, as well as the counter measures imposed by Russia, in addition to the ongoing military conflict between Ukraine and Russia and related sanctions, which could conceivably expand into the surrounding region, remains uncertain; however, both the conflict and related sanctions have resulted and could continue to result in disruptions to trade, commerce, pricing stability, credit availability, supply chain continuity and reduced access to liquidity on acceptable terms, in both Europe and globally, and has introduced significant uncertainty into global markets. As a result, our business and results of operations may be adversely affected by the ongoing military conflict between Ukraine and Russia and related sanctions, particularly to the extent it escalates to involve additional countries, further economic sanctions or wider military conflict. During the three and nine months ended September 30, 2022, the Company experienced supply chain challenges, which it largely attributes to the COVID-19 pandemic and the general disruptions from the ongoing conflict between Ukraine and Russia and related sanctions. While neither the COVID-19 pandemic nor the Ukraine-Russia conflict prevented the Company from operating its business during the three and nine months ended September 30, 2022, it experienced increased cost to secure certain component parts in its products and to produce its products at its contract manufacturers. The Company expects these increased costs to remain high as the COVID-19 pandemic, the Ukraine-Russia conflict and their respective effects persist. As global economic conditions recover from the COVID-19 pandemic, the Ukraine-Russia conflict and the related sanctions, business activity may not recover as quickly as anticipated, and it is not possible at this time to estimate the long-term impact that these and related events could have on the Company’s business, as the impact will depend on future developments, which are highly uncertain and cannot be predicted. For instance, product demand may be reduced due to an economic recession, rising inflation rates, labor shortages, a decrease in corporate capital expenditures, prolonged unemployment, reduction in consumer confidence, adverse macroeconomic events, or any similar negative economic condition. Further, the travel restrictions on the Company’s business have limited its ability to support its global and domestic operations, including providing installation and training and customer service, which has and may continue to slow the pace of its commercial strategy, sales and marketing efforts. These negative effects could have a material impact on the Company’s operations, business, earnings, and liquidity. Significant Accounting Policies During the three and nine months ended September 30, 2022, there were no changes to the Company’s significant accounting policies as described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021. Recently Issued But Not Yet Adopted Accounting Pronouncements In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments (ASU 2016-13) , which amends the impairment model by requiring entities to use a forward looking approach based on expected losses to estimate credit losses on certain types of financial instruments, including trade receivables and available for sale debt securities. The standard is effective for the company beginning in the first quarter of 2023, with early adoption permitted. The Company is currently evaluating the expected impact of ASU 2016-13 on its financial statements. Recently Adopted Accounting Pronouncements In February 2016, the Financial Accounting Standards Board issued Accounting Standards Update 2016-02, “Leases (Topic 842)” (“ASC 842”) which requires lessees to recognize leases on the balance sheet and disclose key information about leasing arrangements. ASC 842 establishes a right-of-use model that requires a lessee to recognize a ROU asset and lease liability on the balance sheet for all leases with a term longer than 12 months. ASC 842 also requires disclosures to meet the objective of enabling users of financial statements to assess the amount, timing, and uncertainty of cash flows arising from leases. The standard was adopted on January 1, 2021, as the Company lost its status as an Emerging Growth Company effective December 31, 2021, and therefore was required to adopt the standard for the year ending December 31, 2021, using the modified retrospective method. Under this transition method, the Company recognized and measured leases that existed at the adoption date in the audited consolidated balance sheet as of January 1, 2021. In connection with the adoption of ASC 842, the Company elected the package of practical expedients requiring no reassessment of whether any expired or existing contracts contain

Net Loss Per Share

Net Loss Per Share	9 Months Ended
	Sep. 30, 2022
Earnings Per Share [Abstract]
Net Loss Per Share	Net Loss Per Share Basic net loss per share is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period. Diluted net loss per share is computed by dividing the net loss by the weighted average number of common shares and common share equivalents outstanding for the period. Common share equivalents are only included when their effect is dilutive. Pre-funded warrants from the Company’s follow-on offering have been treated as if they were common shares outstanding on the date of issuance. The Company’s potentially dilutive securities which include outstanding warrants to purchase stock and outstanding stock options under the Company’s equity incentive plans have been excluded from the computation of diluted net loss per share as they would be anti-dilutive to the net loss per share. Restricted stock is treated as outstanding for accounting purposes. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company’s net loss position. Potentially dilutive securities not included in the calculation of diluted net loss per share attributable to common stockholders because to do so would be anti-dilutive are as follows (in common stock equivalent shares): September 30, September 30, Stock options 24,586,000 10,661,000 Unvested restricted stock 3,420,000 — Warrants 4,356,000 4,361,000 RSUs 163,000 530,000 PSUs 290,000 290,000 Total 32,815,000 15,842,000

Revenue Recognition

Revenue Recognition	9 Months Ended
	Sep. 30, 2022
Revenue from Contract with Customer [Abstract]
Revenue Recognition	Revenue Recognition Revenue by Source Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Instruments $ 1,830,000 $ 1,468,000 $ 5,873,000 $ 3,507,000 Consumables 1,776,000 1,832,000 4,762,000 4,338,000 Total product revenue 3,606,000 3,300,000 10,635,000 7,845,000 Service and other 3,615,000 1,355,000 8,952,000 3,834,000 Total revenue $ 7,221,000 $ 4,655,000 $ 19,587,000 $ 11,679,000 Revenue by Geographic Location Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 $ % $ % $ % $ % Americas $ 3,679,000 51 % $ 2,557,000 55 % $ 9,618,000 49 % $ 6,419,000 55 % EMEA 1,969,000 27 % 1,234,000 27 % 6,317,000 32 % 3,762,000 32 % Asia Pacific 1,573,000 22 % 864,000 18 % 3,652,000 19 % 1,498,000 13 % Total $ 7,221,000 100 % $ 4,655,000 100 % $ 19,587,000 100 % $ 11,679,000 100 % The table above provides revenue from contracts with customers by source and geographic region (based on the customer’s billing address) on a disaggregated basis. Americas consists of North America and South America. EMEA consists of Europe, the Middle East, and Africa. Asia Pacific includes China, Japan, South Korea, Singapore, India and Australia. During the three months ended September 30, 2022, the Company changed the presentation of its revenues from India to be included in the Asia Pacific geographic region. Prior to the three months ended September 30, 2022, the Company had presented revenues from India in the EMEA geographic region. The impact of this change on prior period disclosures is immaterial. For the three months ended September 30, 2022 and 2021, the United States represented 41.8% and 44.2% of total revenue, respectively. For the three months ended September 30, 2022 and 2021, China represented 13.4% and 17.9% of total revenue, respectively. Additionally, for the three months ended September 30, 2021, Canada represented 10.8% of total revenue. For the nine months ended September 30, 2022 and 2021, the United States represented 41.3% and 50.0% of total revenue, respectively. For the nine months ended September 30, 2022, China represented 13.1% of total revenue. No other countries represented greater than 10% of revenue during the three and nine months ended September 30, 2022 and 2021. Remaining Performance Obligations As of September 30, 2022, the estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied was approximately $1.1 million. These remaining performance obligations primarily relate to extended warranty and support and maintenance obligations. The Company expects to recognize approximately 39.0% of this amount as revenue during the remainder of 2022, 51.5% in 2023, and 9.5% in 2024 and thereafter. Warranty revenue is included in service and other revenue. The Company recognized revenue of approximately $0.1 million and $0.1 million during the three months ended September 30, 2022 and 2021, respectively, and revenue of approximately $0.6 million and $0.3 million during the nine months ended September 30, 2022 and 2021, respectively, which was included in the contract liability balance at the end of the previous year.

Balance Sheet Account Details

Balance Sheet Account Details	9 Months Ended
	Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Balance Sheet Account Details	Balance Sheet Account Details Accounts Receivable September 30, December 31, Accounts receivable, net: Accounts receivable, trade $ 6,325,000 $ 5,624,000 Less allowance for doubtful accounts (496,000) (690,000) $ 5,829,000 $ 4,934,000 Inventory The components of inventories are as follows: September 30, December 31, Inventory: Raw materials $ 5,254,000 $ 4,649,000 Work in process 7,072,000 1,660,000 Finished goods 12,720,000 6,078,000 $ 25,046,000 $ 12,387,000 Beginning with the third quarter for the year ended December 31, 2022, the Company revised its classification of its inventory between the categories in the table above. The Company has revised the classification for the December 31, 2021 balance sheet . Intangible Assets Intangible assets that are subject to amortization consisted of the following for the periods presented: September 30, 2022 December 31, 2021 Gross Carrying Amount Accumulated Amortization Net Carrying Amount Gross Carrying Amount Accumulated Amortization Net Carrying Amount Trade name $ 1,630,000 $ (453,000) $ 1,177,000 $ 1,630,000 $ (210,000) $ 1,420,000 Customer relationships 3,950,000 (972,000) 2,978,000 3,950,000 (378,000) 3,572,000 Developed technology 22,800,000 (4,370,000) 18,430,000 22,800,000 (950,000) 21,850,000 Intangibles, net $ 28,380,000 $ (5,795,000) $ 22,585,000 $ 28,380,000 $ (1,538,000) $ 26,842,000 Accrued Expenses Accrued expenses consist of the following: September 30, December 31, Compensation expenses $ 6,756,000 $ 4,529,000 Goods received not invoiced 1,805,000 1,073,000 Customer deposits 6,000 826,000 Taxes payable 763,000 677,000 Insurance 970,000 1,011,000 Accrued royalties 82,000 288,000 Warranty liabilities 337,000 175,000 Accrued clinical study fees 196,000 1,000 Other 827,000 1,114,000 Total $ 11,742,000 $ 9,694,000

Debt

Debt	9 Months Ended
	Sep. 30, 2022
Debt Disclosure [Abstract]
Debt	Debt Paycheck Protection Program On April 17, 2020, the Company received the PPP Loan proceeds of approximately $1.8 million pursuant to the Paycheck Protection Program under the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) administered by the U.S. Small Business Administration (the “SBA”). In February 2021, the Company applied for forgiveness of the PPP Loan, and in March 2021, the PPP Loan, including all accrued interest, was forgiven in full. A gain on forgiveness of Paycheck Protection Program loan of $1.8 million was recognized during the nine months ended September 30, 2021. Innovatus Loan and Security Agreement In May 2021, the outstanding term loan with Innovatus (“Innovatus LSA”) was paid in full, including all accrued interest, the end of term fee, and a prepayment fee for a total of approximately $17.0 million. Interest expense recognized during the nine months ended September 30, 2021 totaled approximately $0.9 million.

Stockholders_ Equity and Stock-

Stockholders’ Equity and Stock-Based Compensation	9 Months Ended
	Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]
Stockholders’ Equity and Stock-Based Compensation	Stockholders’ Equity and Stock-Based Compensation Follow-on Public Offerings On January 12, 2021 and January 25, 2021, the Company completed an underwritten public offering of 33.4 million and 38.3 million shares of common stock, respectively. The price to the public in the offerings on January 12, 2021 and January 15, 2021 was $3.05 and $6.00 per share, respectively. The net proceeds to the Company from the offerings, after deducting the underwriting discounts and commissions and other offering expenses, were $101.5 million and $229.6 million, respectively. Shelf Registration Statements; Ladenburg and Cowen At-the-Market Facilities In August 2020, the Company filed a shelf registration statement on Form S-3 with the SEC covering the offering, issuance and sale of up to $125 million of the Company’s securities, including up to $40 million of common stock, pursuant to an At Market Issuance Sales Agreement, with Ladenburg Thalmann & Co. Inc. acting as sales agent (the “Ladenburg ATM”). During October 2020 through January 2021, the Company sold approximately 33.3 million shares of common stock under the Ladenburg ATM and received net proceeds of $38.0 million after deducting aggregate offering costs. The Company terminated the Ladenburg ATM in March 2021. On January 19, 2021, the Company filed an automatically effective shelf registration statement on Form S-3 with the SEC as a “well-known seasoned issuer,” allowing for the Company to issue an indeterminate number or amount of its securities from time to time in one or more offerings. As of June 30, 2022, as a consequence of the Company’s re-qualification as a “smaller reporting company,” the Company may lose “well-known seasoned issuer” status at the time it files its Annual Report on Form 10-K for the fiscal year ending December 31, 2022 if the worldwide market value of its voting and non-voting common equity held by its non-affiliates does not equal $700.0 million or more, calculated as of a date within 60 days prior to filing such report. If that were to occur and the Company were no longer considered a well-known seasoned issuer, the Company anticipates needing to amend its automatically effective shelf registration statement on Form S-3 prior to its filing of such annual report (or earlier if required by the Securities Act or the rules and regulations of the SEC) in order to sell securities under that Form S-3 on an ongoing basis. On March 23, 2021, the Company entered into a Sales Agreement with Cowen and Company, LLC (“Cowen”) which provides for the sale, in the Company’s sole discretion, of shares of common stock having an aggregate offering price of up to $350.0 million through or to Cowen, acting as sales agent or principal (the “Cowen ATM”). The Company agreed to pay Cowen a commission of up to 3.0% of the aggregate gross proceeds from each sale of shares, reimburse legal fees and disbursements and provide Cowen with customary indemnification and contribution rights. In August and September 2021, the Company sold approximately 2.3 million shares of common stock under the Cowen ATM at an average share price of $6.15 per share, and received gross proceeds of approximately $13.9 million before deducting offering costs of $0.6 million. In August 2022, the Company sold approximately 6.6 million shares of common stock under the Cowen ATM at an average share price of $3.46 per share, and received gross proceeds of approximately $23.1 million before deducting offering costs of $0.6 million. Stock Warrants A summary of the Company’s warrant activity during the nine months ended September 30, 2022 was as follows: Shares of Stock under Warrants Weighted- Weighted- Aggregate Outstanding at January 1, 2022 4,356,000 $ 5.96 1.76 $ 785,000 Granted — — — — Exercised — — — — Canceled — — — — Outstanding at September 30, 2022 4,356,000 $ 5.96 1.01 $ 397,000 Stock Options A summary of the Company’s stock option activity during the nine months ended September 30, 2022 was as follows: Shares of Stock under Stock Options Weighted- Weighted- Aggregate Outstanding at January 1, 2022 12,765,000 $ 4.97 8.9 $ 7,891,000 Granted 14,329,000 2.12 — — Exercised (402,000) 0.66 — 362,000 Canceled (2,106,000) 4.83 — — Outstanding at September 30, 2022 24,586,000 $ 3.39 8.89 $ 3,876,000 Vested and exercisable at September 30, 2022 6,248,000 $ 3.82 7.98 $ 2,288,000 For the three months ended September 30, 2022, the weighted-average grant date fair value of stock options granted was $1.43 per share. For the nine months ended September 30, 2022, the weighted-average grant date fair value of stock options granted was $1.34 per share. Stock-Based Compensation The Company recognized stock-based compensation expense for the periods presented as follows: Three Months Ended Nine Months Ended 2022 2021 2022 2021 Research and development $ 3,606,000 $ 745,000 $ 10,401,000 $ 1,209,000 General and administrative 2,453,000 2,043,000 6,537,000 3,708,000 Total stock-based compensation expense $ 6,059,000 $ 2,788,000 $ 16,938,000 $ 4,917,000 The weighted-average assumptions used in the Black-Scholes option pricing model to determine the fair value of the employee stock option grants during the periods presented were as follows: Three Months Ended Nine Months Ended 2022 2021 2022 2021 Risk-free interest rate 3.1 % 0.9 % 2.2 % 1.1 % Expected volatility 71.0 % 71.4 % 70.3 % 78.3 % Expected term (in years) 6.1 6.0 6.0 6.0 Expected dividend yield 0.0 % 0.0 % 0.0 % 0.0 % Restricted Stock Restricted Stock A restricted stock award in the amount of 5.0 million shares with a grant date fair value of $5.20 a share was granted as part of the acquisition of BioDiscovery. One-third of the Restricted Shares will vest on October 18, 2022 and one-twelfth of the Restricted Shares shall vest every three months following October 18, 2022, subject to continuous service of a key employee. The weighted average remaining contractual term for the restricted stock is 2.1 years as of September 30, 2022. The fair value of the restricted stock award is based on the market value of common stock as of the date of grant and is amortized to expense over the respective vesting period or the service period. On October 4, 2022, the restricted stock award was modified due to the change in employment status of the key employee from full time to emeritus. As a result of the modification, the restricted stock award vested in full on October 4, 2022. The award was revalued on the modification date, resulting in a modified grant date fair value of $2.04 a share. Restricted Stock Units and Performance Stock Units The following table summarizes restricted share unit (“RSU”) activity during the nine months ended September 30, 2022: Stock Units Weighted- Average Grant Date Fair Value per Share Outstanding at January 1, 2022 361,000 $ 4.74 Granted — — Released (198,000) 4.74 Forfeited — — Outstanding at September 30, 2022 163,000 $ 4.74 The total intrinsic value of the RSUs that vested during the nine months ended September 30, 2022 was $0.9 million, determined as of the date of vesting. The weighted average remaining contractual term for the RSUs is 0.6 years as of September 30, 2022. The following table summarizes performance share unit (“PSU”) activity during the nine months ended September 30, 2022: Stock Units Weighted- Average Grant Date Fair Value per Share Outstanding at January 1, 2021 290,000 $ 4.74 Granted — — Released — — Forfeited — — Outstanding at September 30, 2022 290,000 $ 4.74 The weighted average remaining contractual term for the PSUs is 2.6 years as of September 30, 2022. Executive Option Grants On February 15, 2022, the compensation committee of the Company’s board of directors granted various executive officers stock options to purchase an aggregate of 4.3 million shares of common stock at an exercise price of $2.18 a share, in each case with an effective grant date and vesting commencement date of February 15, 2022 (the “Grant Date”). These stock option grants were issued from the 2018 Stock Plan. The shares subject to the option shall vest monthly over 48 months beginning on the one-month anniversary of the Grant Date, such that the option shall be fully vested and exercisable on the four-year anniversary of the Grant Date.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies The Company discounts its lease payments using its incremental borrowing rate as of the commencement of the lease. The Company has determined a weighted-average discount rate of 7% as of September 30, 2022 and December 31, 2021. The operating lease right-of-use asset and operating lease liability as of September 30, 2022 and December 31, 2021 are as follows: September 30, 2022 December 31, 2021 Operating lease right-of-use assets $ 6,030,000 $ 6,691,000 Operating lease liability Current 1,784,000 1,467,000 Non-current 4,694,000 5,288,000 Total operating lease liability $ 6,478,000 $ 6,755,000 For the three and nine months ended September 30, 2022, the Company recorded $0.5 million and $1.5 million, respectively, in expense related to operating leases, including amortized tenant improvement allowances. For the three and nine months ended September 30, 2021, the Company recorded $0.3 million and $0.8 million respectively, in expense related to operating leases, including amortized tenant improvement allowances. The finance lease right-of-use asset and finance lease liability as of September 30, 2022 and December 31, 2021 are as follows: September 30, 2022 December 31, 2021 Finance lease right-of-use assets $ 3,759,000 $ 3,926,000 Finance lease liability Current 288,000 299,000 Non-current 3,626,000 3,642,000 Total finance lease liability $ 3,914,000 $ 3,941,000 For the three and nine months ended September 30, 2022, the Company recorded $0.1 million and $0.4 million, respectively, in expense related to its finance lease. The Company did not hold a finance lease as of September 30, 2021. The future minimum payments under non-cancellable operating and finance leases as of September 30, 2022, are as follows: Operating Leases Finance Lease Remainder of 2022 $ 518,000 $ 79,000 2023 2,149,000 322,000 2024 2,219,000 330,000 2025 2,305,000 338,000 2026 232,000 347,000 Thereafter — 5,948,000 Total future lease payments 7,423,000 7,364,000 Less: imputed interest (945,000) (3,450,000) Total lease liabilities $ 6,478,000 $ 3,914,000 Litigation From time to time, the Company may be subject to potential liabilities under various claims and legal actions that are pending or may be asserted. These matters arise in the ordinary course and conduct of the business. The Company regularly assesses contingencies to determine the degree of probability and range of possible loss for potential accrual in the financial statements. An estimated loss contingency is accrued in the financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Based on the Company’s assessment, it currently does not have any material loss exposure as it is not a defendant in any claims or legal actions. Contingent Consideration

Acquisitions

Acquisitions	9 Months Ended
	Sep. 30, 2022
Business Combination and Asset Acquisition [Abstract]
Acquisitions	Acquisitions BioDiscovery Acquisition In October 2021, the Company completed the acquisition of BioDiscovery, LLC, for a combination of approximately $52.3 million in cash, $40.0 million in shares of Company common stock, and $10.0 million in cash payable based on the achievement of certain milestones. Of the $40.0 million in shares of Company common stock, approximately $26.0 million is subject to vesting based on continuous service. See Note 6 to our unaudited condensed consolidated financial statements for a discussion of the restricted stock vesting terms and accounting treatment. The purchase price allocation for the acquisition of BioDiscovery is preliminary and subject to revision as additional information about the fair value of assets and liabilities becomes available. As permitted under ASC 805, the Company is allowed a measurement period, which may not exceed one year, in which to complete its accounting for the acquisition. During the first quarter of 2022, the Company recorded an increase to the value of acquired contract liabilities in the amount of $0.1 million, with the offset recorded to goodwill. During the three months ended September 30, 2022, the Company recorded an increase to the value of acquired contract liabilities in the amount of $0.2 million, with the offset recorded to goodwill. The purchase price is still subject to adjustment for the final determination of deferred and current tax assets and liabilities. The following is the purchase price for the acquisition of BioDiscovery: Cash $ 52,291,000 Estimated fair value of milestone consideration $ 9,000,000 Return of cash to buyer from escrow $ (694,000) Shares of common stock issued as consideration 2,723,000 Stock price per share on closing date $ 5.20 Value of estimated common stock consideration $ 14,159,000 Total purchase price $ 74,756,000 The total purchase price was allocated to BioDiscovery’s tangible and identifiable intangible assets acquired and liabilities assumed based on their estimated fair values as of the acquisition date, with the excess recorded as goodwill, as follows: Cash and cash equivalents $ 3,205,000 Accounts receivable 1,782,000 Right-of-use assets 3,987,000 Other assets 213,000 Intangible assets 26,800,000 Goodwill 49,294,000 Accounts payable and other accrued liabilities (193,000) Right-of-use liabilities (short-term and long-term) (3,987,000) Deferred tax liability (5,777,000) Contract liabilities (568,000) Net assets acquired $ 74,756,000 The acquisition date fair values of identifiable intangible assets acquired are as follows: Customer relationships $ 3,000,000 Developed technology 22,800,000 Tradename 1,000,000 Fair value of identifiable intangible assets $ 26,800,000 The Company uses the income approach to derive the fair value of the identified intangible assets acquired. This approach calculates fair value by estimating future cash flows attributable to the assets and then discounting these cash flows to a present value using a risk-adjusted discount rate. The developed technology, customer relationships and trade name intangibles are both being amortized on a straight-line basis over their estimated useful lives of five years. Straight-line amortization was determined to be materially consistent with the pattern of expected use of the intangible assets. As the Company began integrating BioDiscovery’s operations with its existing operations during the fourth quarter of 2021, it is not practical or meaningful to distinguish BioDiscovery’s expenses or net income or loss from that of the combined operations. Pro forma Financial Information The unaudited pro forma financial information in the table below summarizes the combined results of operations for the Company and BioDiscovery as if the companies had been combined as of the beginning of the year prior to the acquisition. These amounts have been calculated after applying the Company’s accounting policies and adjusting the results of BioDiscovery to reflect the additional amortization that would have been charged assuming the fair value adjustments to intangible assets had been applied at the beginning of the year prior to the acquisition. The following unaudited pro forma financial information is for informational purposes only and is not necessarily indicative of the results of operations that would have been achieved as if the acquisitions had taken place as of January 1, 2020. Nine Months Ended September 30, Three Months Ended September 30, 2021 2021 Revenue $ 15,986,000 $ 6,519,000 Net loss (51,390,000) (20,911,000) Basic and diluted net loss per share $ (0.19) $ (0.07)

Investments and Fair Value Meas

Investments and Fair Value Measurements	9 Months Ended
	Sep. 30, 2022
Fair Value Disclosures [Abstract]
Investments and Fair Value Measurements	Investments and Fair Value Measurements The Company holds investment securities that consist of highly liquid, investment grade debt securities. The Company determines the fair value of its investment securities based upon one or more valuations reported by its investment accounting and reporting service provider. The investment service provider values the securities using a hierarchical security pricing model that relies primarily on valuations provided by an industry-recognized valuation service. Such valuations may be based on trade prices in active markets for identical assets or liabilities (Level 1 inputs) or valuation models using inputs that are observable either directly or indirectly (Level 2 inputs), such as quoted prices for similar assets or liabilities, yield curves, volatility factors, credit spreads, default rates, loss severity, current market and contractual prices for the underlying instruments or debt, and broker and dealer quotes, as well as other relevant economic measures. The following table presents the Company’s financial assets and liabilities measured at fair value on a recurring basis as of September 30, 2022 and December 31, 2021: September 30, 2022 Total Fair Value and Carrying Value on Balance Sheet Fair Value Measurement Category Level 1 Level 2 Level 3 Assets: Commercial paper $ 48,349,000 $ — $ 48,349,000 $ — Corporate notes/bonds 95,695,000 — 95,695,000 — Securities of government sponsored entities 7,980,000 — 7,980,000 — Total investments: $ 152,024,000 $ — $ 152,024,000 $ — Money market funds $ 12,578,000 $ 12,578,000 $ — $ — Liabilities: Contingent consideration $ 9,303,000 $ — $ — $ 9,303,000 December 31, 2021 Total Fair Value and Carrying Value on Balance Sheet Fair Value Measurement Category Level 1 Level 2 Level 3 Assets: Commercial paper $ 100,860,000 $ — $ 100,860,000 $ — Corporate notes/bonds 125,181,000 — 125,181,000 — Total investments: $ 226,041,000 $ — $ 226,041,000 $ — Money market funds $ 11,126,000 $ 11,126,000 $ — $ — Liabilities: Contingent consideration $ 9,066,000 $ — $ — $ 9,066,000 Money Market Funds are classified as cash equivalents on the balance sheet. As of September 30, 2022 and December 31, 2021, the Company held 51 and 57 securities in an unrealized loss position, respectively. As of September 30, 2022 and December 31, 2021, the Company does not intend to sell these investments and it is not more likely than not that the Company will be required to sell the investments before recovery of their amortized cost basis. The Company does not believe the unrealized losses incurred during the period are due to credit-related factors. The credit ratings of the securities held remain of high quality, and the Company continues to receive payments of interest and principal as they become due, and our expectation is that those payments will continue to be received timely. As such, the Company has not recognized any impairment in its financial statements related to its available for sale investment securities. The fair value of the contingent consideration liability is reassessed on a quarterly basis using the income approach. Assumptions used to estimate the acquisition date fair value of the contingent consideration include the probability of achieving certain milestones and a discount rate of 3%. The fair value measurement of the contingent consideration is based on significant inputs not observed in the market (Level 3 inputs). The Company determined the fair value of the milestone consideration using a scenario-based technique, as the trigger for payment is event driven. The outcome of the milestone consideration is binary, meaning the milestone is either achieved or not achieved, and the only other variable factor is the timing of when the milestone is achieved. The Company determined it is highly likely that the milestone will be achieved and therefore used a 95% probability factor which is applied to the $10.0 million milestone consideration. The change in fair value of the contingent consideration during the three and nine month period ended September 30, 2022 was due to the passage of time. During the nine months ended September 30, 2022, the milestone consideration liability was reclassified from non-current liabilities to current liabilities. Changes in estimated fair value of contingent consideration liability in the nine months ended September 30, 2022 is as follows: Contingent Consideration Liability (Level 3 Measurement) Balance as of January 1, 2022 $ 9,066,000 Liability recorded as a result of current period acquisition — Change in estimated fair value, recorded in selling, general and administrative expenses 237,000 Cash payments — Balance as of September 30, 2022 $ 9,303,000 As of September 30, 2022, the following table summarizes the amortized cost and the unrealized gains (losses) of the available for sale securities: Commercial Paper Corporate Notes/Bonds Securities of Government Sponsored Entities Amortized Cost Unrealized gains (losses) Amortized Cost Unrealized gains (losses) Amortized Cost Unrealized gains (losses) Less than 1 year $ 48,477,000 $ (128,000) $ 78,864,000 $ (1,220,000) $ 5,993,000 $ (2,000) Due after one year through five years — — 18,376,000 (325,000) 1,997,000 (8,000) Total $ 48,477,000 $ (128,000) $ 97,240,000 $ (1,545,000) $ 7,990,000 $ (10,000) As of December 31, 2021, the following table summarizes the amortized cost and the unrealized gains (losses) of the available for sale securities: Commercial Paper Corporate Notes/Bonds Securities of Government Sponsored Entities Amortized Cost Unrealized loss Amortized Cost Unrealized loss Amortized Cost Unrealized gains (losses) Less than 1 year $ 100,929,000 $ (69,000) $ 41,173,000 $ (61,000) $ — $ — Due after one year through five years — — 84,478,000 (409,000) — — Total $ 100,929,000 $ (69,000) $ 125,651,000 $ (470,000) $ — $ — Included in interest income for the three-month period ended September 30, 2022 was interest income related to the Company’s available for sale securities of $0.4 million. Included in interest income for the nine-month period ended September 30, 2022 was interest income related to the Company’s available for sale securities of $0.7 million. All available for sale securities are

Related Party Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2022
Related Party Transactions [Abstract]
Related Party Transactions	Related Party TransactionsThrough the acquisition of BioDiscovery in October 2021, the Company inherited a building lease with a landlord owned by BioDiscovery’s former Director and Chief Executive Officer, who served as the Company’s Chief Informatics Officer from the date of the acquisition through October 2022, and now serves as Chief Informatics Officer, Emeritus. The Company recorded $0.1 million in finance lease costs related to this lease for the three-month period ended September 30, 2022. The Company recorded $0.4 million in finance lease costs related to this lease for the nine-month period ended September 30, 2022.

Organization and Basis of Pre_2

Organization and Basis of Presentation (Policies)	9 Months Ended
	Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of PresentationThe accompanying financial information has been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) for interim reporting purposes. The condensed consolidated financial statements are unaudited. The unaudited condensed consolidated financial statements reflect, in the opinion of the Company’s management, all adjustments, consisting of only normal recurring adjustments, necessary for a fair presentation of financial position, results of operations, changes in equity, and comprehensive loss and cash flows for each period presented in accordance with United States generally accepted accounting principles (“U.S. GAAP”). All intercompany transactions and balances have been eliminated. These interim unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021.
Reclassifications	Reclassifications Certain amounts reported in prior years have been reclassified to conform with the presentation in the current year. These reclassifications had no effect on the reported results of operations.
Liquidity	Liquidity As of September 30, 2022, the Company had approximately $28.2 million in cash and cash equivalents, $152.0 million in available for sale investment securities, and working capital of $184.7 million as a result of common stock offerings executed in the quarters ended December 31, 2020, March 31, 2021, September 30, 2021, and September 30, 2022. The Company believes its available cash, cash equivalents, and available for sale securities will be sufficient to fund operations, obligations as they become due and capital investments for at least the next 12 months. However, the Company expects to continue to incur net losses for the foreseeable future. The Company plans to continue to fund its losses from operations and capital funding needs through a combination of equity offerings, debt financings or other sources, including potential collaborations, licenses and other similar arrangements. If the Company is not able to secure adequate additional funding, the Company may be forced to make reductions in spending, potentially harming the Company’s business.
Recently Issued But Not Yet Adopted and Recently Adopted Accounting Pronouncements	Recently Issued But Not Yet Adopted Accounting Pronouncements In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments (ASU 2016-13) , which amends the impairment model by requiring entities to use a forward looking approach based on expected losses to estimate credit losses on certain types of financial instruments, including trade receivables and available for sale debt securities. The standard is effective for the company beginning in the first quarter of 2023, with early adoption permitted. The Company is currently evaluating the expected impact of ASU 2016-13 on its financial statements. Recently Adopted Accounting Pronouncements In February 2016, the Financial Accounting Standards Board issued Accounting Standards Update 2016-02, “Leases (Topic 842)” (“ASC 842”) which requires lessees to recognize leases on the balance sheet and disclose key information about leasing arrangements. ASC 842 establishes a right-of-use model that requires a lessee to recognize a ROU asset and lease liability on the balance sheet for all leases with a term longer than 12 months. ASC 842 also requires disclosures to meet the objective of enabling users of financial statements to assess the amount, timing, and uncertainty of cash flows arising from leases. The standard was adopted on January 1, 2021, as the Company lost its status as an Emerging Growth Company effective December 31, 2021, and therefore was required to adopt the standard for the year ending December 31, 2021, using the modified retrospective method. Under this transition method, the Company recognized and measured leases that existed at the adoption date in the audited consolidated balance sheet as of January 1, 2021. In connection with the adoption of ASC 842, the Company elected the package of practical expedients requiring no reassessment of whether any expired or existing contracts contain leases, the lease classification of any expired or existing leases, or initial direct costs for any existing leases. The Company also made accounting policy elections not to apply the recognition requirements under ASC 842 to any short-term leases and to account for each separate lease and associated non-lease components as a single lease component for all the Company’s leases. The adoption of this new accounting standard resulted in increased qualitative and quantitative disclosures regarding the amount, timing, and uncertainty of cash flows arising from leases. For further details, see Note 7, Commitments and Contingencies. The adoption of the new standard did not materially impact the Company’s consolidated results of operations. In May 2021, the FASB issued ASU No. 2021-04, Issuer’s Accounting for Certain Modifications or Exchanges for Freestanding Equity-Classified Written Call Options to clarify the accounting for modifications or exchanges of equity-classified warrants. The standard is effective for fiscal years beginning after December 15, 2021. Early adoption is permitted. The Company’s adoption of this accounting standard on January 1, 2022, did not have a material impact on the Company’s unaudited condensed consolidated financial statements and related disclosures.

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	9 Months Ended
	Sep. 30, 2022
Earnings Per Share [Abstract]
Schedule of Potentially Dilutive Securities not Included in Calculation of Diluted Net Loss Per Share Attributable to Common Stockholders	Potentially dilutive securities not included in the calculation of diluted net loss per share attributable to common stockholders because to do so would be anti-dilutive are as follows (in common stock equivalent shares): September 30, September 30, Stock options 24,586,000 10,661,000 Unvested restricted stock 3,420,000 — Warrants 4,356,000 4,361,000 RSUs 163,000 530,000 PSUs 290,000 290,000 Total 32,815,000 15,842,000

Revenue Recognition (Tables)

Revenue Recognition (Tables)	9 Months Ended
	Sep. 30, 2022
Revenue from Contract with Customer [Abstract]
Schedule of Revenue Recognition	Revenue by Source Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Instruments $ 1,830,000 $ 1,468,000 $ 5,873,000 $ 3,507,000 Consumables 1,776,000 1,832,000 4,762,000 4,338,000 Total product revenue 3,606,000 3,300,000 10,635,000 7,845,000 Service and other 3,615,000 1,355,000 8,952,000 3,834,000 Total revenue $ 7,221,000 $ 4,655,000 $ 19,587,000 $ 11,679,000 Revenue by Geographic Location Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 $ % $ % $ % $ % Americas $ 3,679,000 51 % $ 2,557,000 55 % $ 9,618,000 49 % $ 6,419,000 55 % EMEA 1,969,000 27 % 1,234,000 27 % 6,317,000 32 % 3,762,000 32 % Asia Pacific 1,573,000 22 % 864,000 18 % 3,652,000 19 % 1,498,000 13 % Total $ 7,221,000 100 % $ 4,655,000 100 % $ 19,587,000 100 % $ 11,679,000 100 %

Balance Sheet Account Details (

Balance Sheet Account Details (Tables)	9 Months Ended
	Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Accounts Receivable	September 30, December 31, Accounts receivable, net: Accounts receivable, trade $ 6,325,000 $ 5,624,000 Less allowance for doubtful accounts (496,000) (690,000) $ 5,829,000 $ 4,934,000
Schedule of Components of Inventories	The components of inventories are as follows: September 30, December 31, Inventory: Raw materials $ 5,254,000 $ 4,649,000 Work in process 7,072,000 1,660,000 Finished goods 12,720,000 6,078,000 $ 25,046,000 $ 12,387,000
Schedule of Finite-Lived Intangible Assets	Intangible Assets Intangible assets that are subject to amortization consisted of the following for the periods presented: September 30, 2022 December 31, 2021 Gross Carrying Amount Accumulated Amortization Net Carrying Amount Gross Carrying Amount Accumulated Amortization Net Carrying Amount Trade name $ 1,630,000 $ (453,000) $ 1,177,000 $ 1,630,000 $ (210,000) $ 1,420,000 Customer relationships 3,950,000 (972,000) 2,978,000 3,950,000 (378,000) 3,572,000 Developed technology 22,800,000 (4,370,000) 18,430,000 22,800,000 (950,000) 21,850,000 Intangibles, net $ 28,380,000 $ (5,795,000) $ 22,585,000 $ 28,380,000 $ (1,538,000) $ 26,842,000
Schedule of Accrued Liabilities	Accrued expenses consist of the following: September 30, December 31, Compensation expenses $ 6,756,000 $ 4,529,000 Goods received not invoiced 1,805,000 1,073,000 Customer deposits 6,000 826,000 Taxes payable 763,000 677,000 Insurance 970,000 1,011,000 Accrued royalties 82,000 288,000 Warranty liabilities 337,000 175,000 Accrued clinical study fees 196,000 1,000 Other 827,000 1,114,000 Total $ 11,742,000 $ 9,694,000

Stockholders_ Equity and Stoc_2

Stockholders’ Equity and Stock-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]
Schedule of Warrant Activity	A summary of the Company’s warrant activity during the nine months ended September 30, 2022 was as follows: Shares of Stock under Warrants Weighted- Weighted- Aggregate Outstanding at January 1, 2022 4,356,000 $ 5.96 1.76 $ 785,000 Granted — — — — Exercised — — — — Canceled — — — — Outstanding at September 30, 2022 4,356,000 $ 5.96 1.01 $ 397,000
Summary of Stock Option Activity	A summary of the Company’s stock option activity during the nine months ended September 30, 2022 was as follows: Shares of Stock under Stock Options Weighted- Weighted- Aggregate Outstanding at January 1, 2022 12,765,000 $ 4.97 8.9 $ 7,891,000 Granted 14,329,000 2.12 — — Exercised (402,000) 0.66 — 362,000 Canceled (2,106,000) 4.83 — — Outstanding at September 30, 2022 24,586,000 $ 3.39 8.89 $ 3,876,000 Vested and exercisable at September 30, 2022 6,248,000 $ 3.82 7.98 $ 2,288,000
Summary of Recognized Stock-Based Compensation Expense	The Company recognized stock-based compensation expense for the periods presented as follows: Three Months Ended Nine Months Ended 2022 2021 2022 2021 Research and development $ 3,606,000 $ 745,000 $ 10,401,000 $ 1,209,000 General and administrative 2,453,000 2,043,000 6,537,000 3,708,000 Total stock-based compensation expense $ 6,059,000 $ 2,788,000 $ 16,938,000 $ 4,917,000
Schedule of Weighted-Average Assumptions in Black -Scholes Option Pricing Model	The weighted-average assumptions used in the Black-Scholes option pricing model to determine the fair value of the employee stock option grants during the periods presented were as follows: Three Months Ended Nine Months Ended 2022 2021 2022 2021 Risk-free interest rate 3.1 % 0.9 % 2.2 % 1.1 % Expected volatility 71.0 % 71.4 % 70.3 % 78.3 % Expected term (in years) 6.1 6.0 6.0 6.0 Expected dividend yield 0.0 % 0.0 % 0.0 % 0.0 %
Share-based Payment Arrangement, Restricted Stock Unit, Activity	The following table summarizes restricted share unit (“RSU”) activity during the nine months ended September 30, 2022: Stock Units Weighted- Average Grant Date Fair Value per Share Outstanding at January 1, 2022 361,000 $ 4.74 Granted — — Released (198,000) 4.74 Forfeited — — Outstanding at September 30, 2022 163,000 $ 4.74 The following table summarizes performance share unit (“PSU”) activity during the nine months ended September 30, 2022: Stock Units Weighted- Average Grant Date Fair Value per Share Outstanding at January 1, 2021 290,000 $ 4.74 Granted — — Released — — Forfeited — — Outstanding at September 30, 2022 290,000 $ 4.74

Commitment and Contingencies (T

Commitment and Contingencies (Tables)	9 Months Ended
	Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Lessee, Operating Lease, Disclosure Information	The operating lease right-of-use asset and operating lease liability as of September 30, 2022 and December 31, 2021 are as follows: September 30, 2022 December 31, 2021 Operating lease right-of-use assets $ 6,030,000 $ 6,691,000 Operating lease liability Current 1,784,000 1,467,000 Non-current 4,694,000 5,288,000 Total operating lease liability $ 6,478,000 $ 6,755,000
Lessee, Finance Lease, Disclosure Information	The finance lease right-of-use asset and finance lease liability as of September 30, 2022 and December 31, 2021 are as follows: September 30, 2022 December 31, 2021 Finance lease right-of-use assets $ 3,759,000 $ 3,926,000 Finance lease liability Current 288,000 299,000 Non-current 3,626,000 3,642,000 Total finance lease liability $ 3,914,000 $ 3,941,000
Lessee, Operating Lease, Liability, Maturity	The future minimum payments under non-cancellable operating and finance leases as of September 30, 2022, are as follows: Operating Leases Finance Lease Remainder of 2022 $ 518,000 $ 79,000 2023 2,149,000 322,000 2024 2,219,000 330,000 2025 2,305,000 338,000 2026 232,000 347,000 Thereafter — 5,948,000 Total future lease payments 7,423,000 7,364,000 Less: imputed interest (945,000) (3,450,000) Total lease liabilities $ 6,478,000 $ 3,914,000

Acquisitions (Tables)

Acquisitions (Tables)	9 Months Ended
	Sep. 30, 2022
Business Combination and Asset Acquisition [Abstract]
Schedule of Business Acquisitions	The following is the purchase price for the acquisition of BioDiscovery: Cash $ 52,291,000 Estimated fair value of milestone consideration $ 9,000,000 Return of cash to buyer from escrow $ (694,000) Shares of common stock issued as consideration 2,723,000 Stock price per share on closing date $ 5.20 Value of estimated common stock consideration $ 14,159,000 Total purchase price $ 74,756,000
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	The total purchase price was allocated to BioDiscovery’s tangible and identifiable intangible assets acquired and liabilities assumed based on their estimated fair values as of the acquisition date, with the excess recorded as goodwill, as follows: Cash and cash equivalents $ 3,205,000 Accounts receivable 1,782,000 Right-of-use assets 3,987,000 Other assets 213,000 Intangible assets 26,800,000 Goodwill 49,294,000 Accounts payable and other accrued liabilities (193,000) Right-of-use liabilities (short-term and long-term) (3,987,000) Deferred tax liability (5,777,000) Contract liabilities (568,000) Net assets acquired $ 74,756,000
Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination	The acquisition date fair values of identifiable intangible assets acquired are as follows: Customer relationships $ 3,000,000 Developed technology 22,800,000 Tradename 1,000,000 Fair value of identifiable intangible assets $ 26,800,000
Business Acquisition, Pro Forma Information	The following unaudited pro forma financial information is for informational purposes only and is not necessarily indicative of the results of operations that would have been achieved as if the acquisitions had taken place as of January 1, 2020. Nine Months Ended September 30, Three Months Ended September 30, 2021 2021 Revenue $ 15,986,000 $ 6,519,000 Net loss (51,390,000) (20,911,000) Basic and diluted net loss per share $ (0.19) $ (0.07)

Investments and Fair Value Me_2

Investments and Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2022
Fair Value Disclosures [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	The following table presents the Company’s financial assets and liabilities measured at fair value on a recurring basis as of September 30, 2022 and December 31, 2021: September 30, 2022 Total Fair Value and Carrying Value on Balance Sheet Fair Value Measurement Category Level 1 Level 2 Level 3 Assets: Commercial paper $ 48,349,000 $ — $ 48,349,000 $ — Corporate notes/bonds 95,695,000 — 95,695,000 — Securities of government sponsored entities 7,980,000 — 7,980,000 — Total investments: $ 152,024,000 $ — $ 152,024,000 $ — Money market funds $ 12,578,000 $ 12,578,000 $ — $ — Liabilities: Contingent consideration $ 9,303,000 $ — $ — $ 9,303,000 December 31, 2021 Total Fair Value and Carrying Value on Balance Sheet Fair Value Measurement Category Level 1 Level 2 Level 3 Assets: Commercial paper $ 100,860,000 $ — $ 100,860,000 $ — Corporate notes/bonds 125,181,000 — 125,181,000 — Total investments: $ 226,041,000 $ — $ 226,041,000 $ — Money market funds $ 11,126,000 $ 11,126,000 $ — $ — Liabilities: Contingent consideration $ 9,066,000 $ — $ — $ 9,066,000
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation	Changes in estimated fair value of contingent consideration liability in the nine months ended September 30, 2022 is as follows: Contingent Consideration Liability (Level 3 Measurement) Balance as of January 1, 2022 $ 9,066,000 Liability recorded as a result of current period acquisition — Change in estimated fair value, recorded in selling, general and administrative expenses 237,000 Cash payments — Balance as of September 30, 2022 $ 9,303,000
Marketable Securities	As of September 30, 2022, the following table summarizes the amortized cost and the unrealized gains (losses) of the available for sale securities: Commercial Paper Corporate Notes/Bonds Securities of Government Sponsored Entities Amortized Cost Unrealized gains (losses) Amortized Cost Unrealized gains (losses) Amortized Cost Unrealized gains (losses) Less than 1 year $ 48,477,000 $ (128,000) $ 78,864,000 $ (1,220,000) $ 5,993,000 $ (2,000) Due after one year through five years — — 18,376,000 (325,000) 1,997,000 (8,000) Total $ 48,477,000 $ (128,000) $ 97,240,000 $ (1,545,000) $ 7,990,000 $ (10,000) As of December 31, 2021, the following table summarizes the amortized cost and the unrealized gains (losses) of the available for sale securities: Commercial Paper Corporate Notes/Bonds Securities of Government Sponsored Entities Amortized Cost Unrealized loss Amortized Cost Unrealized loss Amortized Cost Unrealized gains (losses) Less than 1 year $ 100,929,000 $ (69,000) $ 41,173,000 $ (61,000) $ — $ — Due after one year through five years — — 84,478,000 (409,000) — — Total $ 100,929,000 $ (69,000) $ 125,651,000 $ (470,000) $ — $ —

Organization and Basis of Pre_3

Organization and Basis of Presentation (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash and cash equivalents	$ 28,166	$ 24,571
Investments	152,024	$ 226,041
Working capital	$ 184,700

Net Loss Per Share (Details)

Net Loss Per Share (Details) - shares shares in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share amount (in shares)	32,815	15,842
Stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share amount (in shares)	24,586	10,661
Unvested restricted stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share amount (in shares)	3,420	0
Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share amount (in shares)	4,356	4,361
RSUs
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share amount (in shares)	163	530
PSUs
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share amount (in shares)	290	290

Revenue Recognition - Revenue b

Revenue Recognition - Revenue by Source and Geographic Location (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Disaggregation of Revenue [Line Items]
Revenue	$ 7,221	$ 4,655	$ 19,587	$ 11,679
Americas
Disaggregation of Revenue [Line Items]
Revenue	3,679	2,557	9,618	6,419
EMEA
Disaggregation of Revenue [Line Items]
Revenue	1,969	1,234	6,317	3,762
Asia Pacific
Disaggregation of Revenue [Line Items]
Revenue	$ 1,573	$ 864	$ 3,652	$ 1,498
Revenue from Contract with Customer | Geographic Concentration Risk
Disaggregation of Revenue [Line Items]
Concentration risk percentage	100%	100%	100%	100%
Revenue from Contract with Customer | Geographic Concentration Risk | Americas
Disaggregation of Revenue [Line Items]
Concentration risk percentage	51%	55%	49%	55%
Revenue from Contract with Customer | Geographic Concentration Risk | EMEA
Disaggregation of Revenue [Line Items]
Concentration risk percentage	27%	27%	32%	32%
Revenue from Contract with Customer | Geographic Concentration Risk | Asia Pacific
Disaggregation of Revenue [Line Items]
Concentration risk percentage	22%	18%	19%	13%
Product revenue
Disaggregation of Revenue [Line Items]
Revenue	$ 3,606	$ 3,300	$ 10,635	$ 7,845
Instruments
Disaggregation of Revenue [Line Items]
Revenue	1,830	1,468	5,873	3,507
Consumables
Disaggregation of Revenue [Line Items]
Revenue	1,776	1,832	4,762	4,338
Service and other
Disaggregation of Revenue [Line Items]
Revenue	$ 3,615	$ 1,355	$ 8,952	$ 3,834

Revenue Recognition - Narrative

Revenue Recognition - Narrative (Details) - Geographic Concentration Risk - Revenue Benchmark	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
United States
Disaggregation of Revenue [Line Items]
Concentration risk percentage	41.80%	44.20%	41.30%	50%
China
Disaggregation of Revenue [Line Items]
Concentration risk percentage	13.40%	17.90%	13.10%
Canada
Disaggregation of Revenue [Line Items]
Concentration risk percentage		10.80%

Revenue Recognition - Remaining

Revenue Recognition - Remaining Performance Obligations (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Performance obligation	$ 1.1		$ 1.1
Revenue recognized	$ 0.1	$ 0.1	$ 0.6	$ 0.3
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-10-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Performance obligation, percentage	39%		39%
Timing of satisfaction of remaining performance obligation	3 months		3 months
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Performance obligation, percentage	51.50%		51.50%
Timing of satisfaction of remaining performance obligation	1 year		1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Performance obligation, percentage	9.50%		9.50%
Timing of satisfaction of remaining performance obligation	1 year		1 year

Balance Sheet Account Details -

Balance Sheet Account Details - Schedule of Accounts Receivable (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accounts receivable, trade	$ 6,325	$ 5,624
Less allowance for doubtful accounts	(496)	(690)
Accounts receivable, net	$ 5,829	$ 4,934

Balance Sheet Account Details_2

Balance Sheet Account Details - Schedule of Components of Inventories (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Raw materials	$ 5,254	$ 4,649
Work in process	7,072	1,660
Finished goods	12,720	6,078
Inventory, net	$ 25,046	$ 12,387

Balance Sheet Account Details_3

Balance Sheet Account Details - Summary of Intangible Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 28,380	$ 28,380
Accumulated Amortization	(5,795)	(1,538)
Net Carrying Amount	22,585	26,842
Tradename
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	1,630	1,630
Accumulated Amortization	(453)	(210)
Net Carrying Amount	1,177	1,420
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	3,950	3,950
Accumulated Amortization	(972)	(378)
Net Carrying Amount	2,978	3,572
Developed technology
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	22,800	22,800
Accumulated Amortization	(4,370)	(950)
Net Carrying Amount	$ 18,430	$ 21,850

Balance Sheet Account Details_4

Balance Sheet Account Details - Schedule of Accrued Expenses (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Compensation expenses	$ 6,756	$ 4,529
Goods received not invoiced	1,805	1,073
Customer deposits	6	826
Taxes payable	763	677
Insurance	970	1,011
Accrued royalties	82	288
Warranty liabilities	337	175
Accrued clinical study fees	196	1
Other	827	1,114
Accrued expenses	$ 11,742	$ 9,694

Debt (Details)

Debt (Details) - USD ($) $ in Thousands		1 Months Ended	3 Months Ended		9 Months Ended
	Apr. 17, 2020	May 31, 2021	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Debt Instrument [Line Items]
Gain on forgiveness of PPP Loan			$ 0	$ 0	$ 0	$ 1,775
Repayments of debt					0	17,010
Interest expense			$ 73	$ 2	$ 223	873
Loan Under Paycheck Protection Program | Unsecured Loan
Debt Instrument [Line Items]
Proceeds from issuance of debt	$ 1,800
Gain on forgiveness of PPP Loan						$ 1,800
Innovatus LSA
Debt Instrument [Line Items]
Repayments of debt		$ 17,000

Stockholders_ Equity and Stoc_3

Stockholders’ Equity and Stock-Based Compensation - Narrative (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Millions

1 Months Ended

2 Months Ended

3 Months Ended

4 Months Ended

9 Months Ended

Feb. 15, 2022

Mar. 23, 2021

Jan. 25, 2021

Jan. 12, 2021

Aug. 31, 2022

Oct. 31, 2021

Sep. 30, 2021

Sep. 30, 2022

Jan. 31, 2021

Sep. 30, 2022

Oct. 04, 2022

Dec. 31, 2021

Aug. 31, 2020

Class of Stock [Line Items]

Number of shares issued (in shares)

38,300

33,400

6,600

2,300

33,300

Average share price (in dollars per share)

$ 6

$ 3.05

$ 3.46

$ 6.15

Net proceeds

$ 229.6

$ 101.5

$ 23.1

$ 13.9

$ 38

Authorized amount of stock to be issued

$ 125

Offering costs

$ 0.6

$ 0.6

Weighted-average grant date fair value (in dollars per share)

$ 1.43

$ 1.34

Granted (in shares)

14,329

Granted (in dollars per share)

$ 2.12

Common Stock

Class of Stock [Line Items]

Authorized amount of stock to be issued

$ 40

Executive Officer

Class of Stock [Line Items]

Granted (in shares)

4,300

Granted (in dollars per share)

$ 2.18

Restricted Stock

Class of Stock [Line Items]

Vesting period

2 years 1 month 6 days

Restricted Stock | Subsequent Event

Class of Stock [Line Items]

Grant fair value (in dollars per share)

$ 2.04

Restricted Stock | Vesting on October 18, 2022

Class of Stock [Line Items]

Vesting percentage

33%

Restricted Stock | Vesting every three months following October 18, 2022

Class of Stock [Line Items]

Vesting percentage

8%

Restricted Stock | BioDiscovery

Class of Stock [Line Items]

Units granted (in shares)

5,000

Granted (in dollars per share)

$ 5.20

RSUs

Class of Stock [Line Items]

Units granted (in shares)

0

Granted (in dollars per share)

$ 0

Grant fair value (in dollars per share)

4.74

$ 4.74

$ 4.74

Total intrinsic value

$ 0.9

Weighted average remaining contractual term

7 months 6 days

PSUs

Class of Stock [Line Items]

Units granted (in shares)

0

Granted (in dollars per share)

$ 0

Grant fair value (in dollars per share)

$ 4.74

$ 4.74

$ 4.74

Weighted average remaining contractual term

2 years 7 months 6 days

Option | Executive Officer

Class of Stock [Line Items]

Vesting period

48 months

Cowen

Class of Stock [Line Items]

Aggregate offering price

$ 350

Commission fee

3%

Stockholders_ Equity and Stoc_4

Stockholders’ Equity and Stock-Based Compensation - Warrant Activity (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Shares of Stock under Warrants
Beginning balance (in shares)	4,356
Granted (in shares)	0
Exercised (in shares)	0
Canceled (in shares)	0
Ending balance (in shares)	4,356	4,356
Weighted- Average Exercise Price
Beginning balance (in dollars per share)	$ 5.96
Ending balance (in dollars per share)	$ 5.96	$ 5.96
Weighted- Average Remaining Contractual Term
Balance	1 year 3 days	1 year 9 months 3 days
Aggregate Intrinsic Value
Beginning balance	$ 785
Ending balance	$ 397	$ 785

Stockholders_ Equity and Stoc_5

Stockholders’ Equity and Stock-Based Compensation - Summary of Stock Option Activity (Details) $ / shares in Units, shares in Thousands, $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2022 USD ($) $ / shares shares	Dec. 31, 2021 USD ($) $ / shares shares
Shares of Stock under Stock Options
Beginning balance (in shares) | shares	12,765
Granted (in shares) | shares	14,329
Exercised (in shares) | shares	(402)
Canceled (in shares) | shares	(2,106)
Ending balance (in shares) | shares	24,586	12,765
Vested and exercisable (in shares) | shares	6,248
Weighted- Average Exercise Price
Beginning balance (in dollars per share) | $ / shares	$ 4.97
Granted (in dollars per share) | $ / shares	2.12
Exercised (in dollars per share) | $ / shares	0.66
Canceled (in dollars per share) | $ / shares	4.83
Ending balance (in dollars per share) | $ / shares	3.39	$ 4.97
Vested and exercisable (in dollars per share) | $ / shares	$ 3.82
Weighted- Average Remaining Contractual Term
Outstanding (in years)	8 years 10 months 20 days	8 years 10 months 24 days
Vested and exercisable (in years)	7 years 11 months 23 days
Aggregate Intrinsic Value
Beginning balance | $	$ 7,891
Exercised | $	362
Ending balance | $	3,876	$ 7,891
Vested and exercisable | $	$ 2,288

Stockholders_ Equity and Stoc_6

Stockholders’ Equity and Stock-Based Compensation - Recognized Stock-Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	$ 6,059	$ 2,788	$ 16,938	$ 4,917
Research and development
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	3,606	745	10,401	1,209
General and administrative
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	$ 2,453	$ 2,043	$ 6,537	$ 3,708

Stockholders_ Equity and Stoc_7

Stockholders’ Equity and Stock-Based Compensation - Assumptions (Details)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Share-Based Payment Arrangement [Abstract]
Risk-free interest rate	3.10%	0.90%	2.20%	1.10%
Expected volatility	71%	71.40%	70.30%	78.30%
Expected term (in years)	6 years 1 month 6 days	6 years	6 years	6 years
Expected dividend yield	0%	0%	0%	0%

Stockholders_ Equity and Stoc_8

Stockholders’ Equity and Stock-Based Compensation - Restricted Stock and Performance Stock Activity (Details) shares in Thousands	9 Months Ended
	Sep. 30, 2022 $ / shares shares
RSUs
Stock Units
Beginning balance (in shares) | shares	361
Units granted (in shares) | shares	0
Released (in shares) | shares	(198)
Forfeited (in shares) | shares	0
Ending balance (in shares) | shares	163
Weighted- Average Grant Date Fair Value per Share
Beginning balance (in dollars per share) | $ / shares	$ 4.74
Granted (in dollars per share) | $ / shares	0
Released (in dollars per share) | $ / shares	4.74
Forfeited (in dollars per share) | $ / shares	0
Ending balance (in dollars per share) | $ / shares	$ 4.74
PSUs
Stock Units
Beginning balance (in shares) | shares	290
Units granted (in shares) | shares	0
Released (in shares) | shares	0
Forfeited (in shares) | shares	0
Ending balance (in shares) | shares	290
Weighted- Average Grant Date Fair Value per Share
Beginning balance (in dollars per share) | $ / shares	$ 4.74
Granted (in dollars per share) | $ / shares	0
Released (in dollars per share) | $ / shares	0
Forfeited (in dollars per share) | $ / shares	0
Ending balance (in dollars per share) | $ / shares	$ 4.74

Commitments and Contingencies -

Commitments and Contingencies - Narrative (Details) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Estimated incremental borrowing rate			7%		7%
Operating lease expense	$ 500,000	$ 300,000	$ 1,500,000	$ 800,000
Total finance lease costs	$ 100,000		$ 400,000	$ 0

Commitments and Contingencies_2

Commitments and Contingencies - Operating Lease Right of Use Assets and Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Operating lease right-of-use assets	$ 6,030	$ 6,691
Operating lease liability, current	1,784	1,467
Operating lease liability, noncurrent	4,694	5,288
Total operating lease liability	$ 6,478	$ 6,755

Commitments and Contingencies_3

Commitments and Contingencies - Finance Lease Right of Use Assets and Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Finance lease right-of-use assets	$ 3,759	$ 3,926
Finance lease liability, current	288	299
Finance lease liability, noncurrent	3,626	3,642
Total finance lease liability	$ 3,914	$ 3,941

Commitments and Contingencies_4

Commitments and Contingencies - Summary of Undiscounted Future Non-Cancellable Lease Payments Under Leases (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Operating Leases
Remainder of 2022	$ 518
2023	2,149
2024	2,219
2025	2,305
2026	232
Thereafter	0
Total future lease payments	7,423
Less: imputed interest	(945)
Total lease liabilities	6,478	$ 6,755
Finance Lease
Remainder of 2022	79
2023	322
2024	330
2025	338
2026	347
Thereafter	5,948
Total future lease payments	7,364
Less: imputed interest	(3,450)
Total lease liabilities	$ 3,914	$ 3,941

Acquisitions - Narrative (Detai

Acquisitions - Narrative (Details) - BioDiscovery - USD ($) $ in Thousands, shares in Millions	1 Months Ended	3 Months Ended		9 Months Ended
	Oct. 31, 2021	Sep. 30, 2022	Mar. 31, 2022	Sep. 30, 2022
Business Acquisition [Line Items]
Cash consideration transferred in acquisition	$ 52,291
Consideration transferred, common stock (in shares)	40
Milestone payment payable	$ 10,000
Value of shares subject to vesting	$ 26,000
Increase in acquired contract liabilities		$ 200	$ 100
Intangible assets useful life				5 years

Acquisitions - Acquisition Purc

Acquisitions - Acquisition Purchase Price (Details) - BioDiscovery $ / shares in Units, shares in Thousands, $ in Thousands	1 Months Ended
	Oct. 31, 2021 USD ($) $ / shares shares
Business Acquisition [Line Items]
Cash	$ 52,291
Estimated fair value of milestone consideration	9,000
Return of cash to buyer from escrow	$ (694)
Shares of common stock issued as consideration (in shares) | shares	2,723
Stock price per share on Effective Date (in dollars per share) | $ / shares	$ 5.20
Value of estimated common stock consideration	$ 14,159
Total purchase price	$ 74,756

Acquisitions - Fair Value of Ta

Acquisitions - Fair Value of Tangible and Identifiable Assets Acquired and Liabilities Assumed (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021	Oct. 31, 2021
Business Acquisition [Line Items]
Goodwill	$ 56,466	$ 56,160
BioDiscovery
Business Acquisition [Line Items]
Cash and cash equivalents			$ 3,205
Accounts receivable			1,782
Right-of-use assets			3,987
Other assets			213
Intangible assets			26,800
Goodwill			49,294
Accounts payable and other accrued liabilities			(193)
Right-of-use liabilities (short-term and long-term)			(3,987)
Deferred tax liability			(5,777)
Contract liabilities			(568)
Net assets acquired			$ 74,756

Acquisitions - Identifiable Int

Acquisitions - Identifiable Intangible Assets (Details) - BioDiscovery $ in Thousands	Oct. 31, 2021 USD ($)
Business Acquisition [Line Items]
Intangible assets	$ 26,800
Customer relationships
Business Acquisition [Line Items]
Intangible assets	3,000
Developed technology
Business Acquisition [Line Items]
Intangible assets	22,800
Tradename
Business Acquisition [Line Items]
Intangible assets	$ 1,000

Acquisitions - Pro Forma Inform

Acquisitions - Pro Forma Information (Details) - BioDiscovery - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2021
Business Acquisition [Line Items]
Revenue	$ 6,519	$ 15,986
Net loss	$ (20,911)	$ (51,390)
Basic net loss per share (in dollars per share)	$ (0.07)	$ (0.19)
Diluted net loss per share (in dollars per share)	$ (0.07)	$ (0.19)

Investments and Fair Value Me_3

Investments and Fair Value Measurements - Financial Assets and Liabilities (Details) - Fair Value, Recurring - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Contingent consideration
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Liabilities	$ 9,303	$ 9,066
Total investments
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets	152,024	226,041
Total investments | Commercial paper
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets	48,349	100,860
Total investments | Corporate notes/bonds
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets	95,695	125,181
Total investments | Securities of government sponsored entities
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets	7,980
Money market funds
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets	12,578	11,126
Level 1 | Contingent consideration
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Liabilities	0	0
Level 1 | Total investments
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets	0	0
Level 1 | Total investments | Commercial paper
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets	0	0
Level 1 | Total investments | Corporate notes/bonds
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets	0	0
Level 1 | Total investments | Securities of government sponsored entities
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets	0
Level 1 | Money market funds
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets	12,578	11,126
Level 2 | Contingent consideration
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Liabilities	0	0
Level 2 | Total investments
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets	152,024	226,041
Level 2 | Total investments | Commercial paper
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets	48,349	100,860
Level 2 | Total investments | Corporate notes/bonds
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets	95,695	125,181
Level 2 | Total investments | Securities of government sponsored entities
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets	7,980
Level 2 | Money market funds
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets	0	0
Level 3 | Contingent consideration
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Liabilities	9,303	9,066
Level 3 | Total investments
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets	0	0
Level 3 | Total investments | Commercial paper
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets	0	0
Level 3 | Total investments | Corporate notes/bonds
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets	0	0
Level 3 | Total investments | Securities of government sponsored entities
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets	0
Level 3 | Money market funds
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets	$ 0	$ 0

Investments and Fair Value Me_4

Investments and Fair Value Measurements - Narrative (Details) $ in Millions	3 Months Ended	9 Months Ended
	Sep. 30, 2022 USD ($) security	Sep. 30, 2022 USD ($) security	Dec. 31, 2021 security
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Number of securities in an unrealized loss position | security	51	51	57
Milestone payment		$ 10
Interest income	$ 0.4	$ 0.7
Contingent consideration | Measurement Input, Discount Rate
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Measurement input	0.03	0.03
Contingent consideration | Measurement Input, Probability Factor
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Measurement input	0.95	0.95

Investments and Fair Value Me_5

Investments and Fair Value Measurements - Contingent Consideration Liability (Details) - Contingent consideration $ in Thousands	9 Months Ended
	Sep. 30, 2022 USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	$ 9,066
Liability recorded as a result of current period acquisition	0
Change in estimated fair value, recorded in selling, general and administrative expenses	237
Cash payments	0
Ending balance	$ 9,303

Investments and Fair Value Me_6

Investments and Fair Value Measurements - Amortized Cost and Unrealized Gains (Losses) (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Commercial paper
Amortized Cost
Less than 1 year	$ 48,477	$ 100,929
Due after one year through five years	0	0
Total	48,477	100,929
Unrealized gains (losses)
Less than 1 year	(128)	(69)
Due after one year through five years	0	0
Total	(128)	(69)
Corporate notes/bonds
Amortized Cost
Less than 1 year	78,864	41,173
Due after one year through five years	18,376	84,478
Total	97,240	125,651
Unrealized gains (losses)
Less than 1 year	(1,220)	(61)
Due after one year through five years	(325)	(409)
Total	(1,545)	(470)
Securities of Government Sponsored Entities
Amortized Cost
Less than 1 year	5,993	0
Due after one year through five years	1,997	0
Total	7,990	0
Unrealized gains (losses)
Less than 1 year	(2)	0
Due after one year through five years	(8)	0
Total	$ (10)	$ 0

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($)	3 Months Ended	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2022	Sep. 30, 2021
Related Party Transaction [Line Items]
Total finance lease costs	$ 100,000	$ 400,000	$ 0
Affiliated Entity
Related Party Transaction [Line Items]
Total finance lease costs	$ 100,000	$ 400,000